Aurdan Capital Management LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 20.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 37,989 shares of the healthcare product maker's stock after selling 9,895 shares during the period. Abbott Laboratories makes up approximately 1.9% of Aurdan Capital Management LLC's investment portfolio, making the stock its 14th largest holding. Aurdan Capital Management LLC's holdings in Abbott Laboratories were worth $5,039,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Cim LLC grew its stake in Abbott Laboratories by 0.4% during the 4th quarter. Cim LLC now owns 16,967 shares of the healthcare product maker's stock worth $1,919,000 after buying an additional 73 shares during the last quarter. Capital Square LLC grew its stake in shares of Abbott Laboratories by 2.7% in the fourth quarter. Capital Square LLC now owns 2,941 shares of the healthcare product maker's stock worth $368,000 after purchasing an additional 77 shares in the last quarter. Consilium Wealth Advisory LLC grew its stake in shares of Abbott Laboratories by 2.1% in the first quarter. Consilium Wealth Advisory LLC now owns 3,822 shares of the healthcare product maker's stock worth $507,000 after purchasing an additional 78 shares in the last quarter. Cyrus J. Lawrence LLC grew its stake in shares of Abbott Laboratories by 9.0% in the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock worth $107,000 after purchasing an additional 79 shares in the last quarter. Finally, Edge Financial Advisors LLC grew its stake in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.
Insider Activity at Abbott Laboratories
In other news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company's stock.
Abbott Laboratories Stock Performance
Shares of ABT stock opened at $133.41 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The stock's 50-day moving average is $133.49 and its two-hundred day moving average is $128.72. The firm has a market cap of $232.11 billion, a P/E ratio of 17.30, a PEG ratio of 2.53 and a beta of 0.73.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.77%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories's payout ratio is presently 30.61%.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on ABT shares. Wells Fargo & Company upped their price objective on Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Barclays upped their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective for the company. Morgan Stanley upped their price objective on Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a report on Thursday, April 17th. Finally, Evercore ISI upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday. Six equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $143.11.
Get Our Latest Stock Analysis on Abbott Laboratories
Abbott Laboratories Company Profile
(
Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read More
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.